Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society

Table 8 Partial relation of oral antidiabetic drugs at combination therapy: two substances in a single pill

Therapeutic classes	Chemical Denomination	Commercial Denomination	Action and Dosage Mechanism
biguanide + sulphonylurea	metformin + glibenclamide	Glucovance^® Merck	Peripheral action insulin sensitizer (metformin) + long-acting secretagogue of insulin (glibenclamide). Dosage: 250 mg metformin+1.25 mg glibenclamide 500 mg metformin + 2.5 mg glibenclamide 500 mg metformin + 5 mg glibenclamide.
glitazone + biguanides	rosiglitazone + metformin	Avandamet^® Glaxo	Combination of two peripheral action insulin sensitizers, with different action Dosage: 2 mg rosiglitazone + 500 mg metformin 4 mg rosiglitazone + 500 mg metformin.
Incretin mimetic + metformin	sitagliptin + metformin	Janumet^® MSD	DPP-4inhibitor + peripheral action insulin sensitizer (metformin). Dosage: 50 mg sitagliptin + 500, 850 or 1,000 mg metformin
Incretin mimetic + metformin	vildagliptin + metformin	Galvus Met^® Novartis	DPP-4 inhibitor + peripheral action insulin sensitizer (metformin). Dosage: 50 mg vildagliptin + 500, 850 or 1,000 mg metformin

This table presents only a partial list of commercial medications of various drugs and does not represent a specific recommendation of any commercial brand.

ISSN: 1758-5996